(Q34441137)

2 August 2017

1 reference

title

Human therapeutic antibodies (English)

1 reference

2 August 2017

1 reference

Borrebaeck CA

1

1 reference

2 August 2017

Carlsson R

series ordinal

2

1 reference

2 August 2017

publication date

1 August 2001

1 reference

Current Opinion in Pharmacology

2 August 2017

published in

1 reference

2 August 2017

volume

1

1 reference

2 August 2017

issue

4

1 reference

2 August 2017

page(s)

404-408

1 reference

Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics?

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Replacing the complementarity-determining regions in a human antibody with those from a mouse

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Phage antibodies: filamentous phage displaying antibody variable domains

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Antibody humanization: a case of the 'Emperor's new clothes'?

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Clinical trials of antibody therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Human mAbs produced by primary in-vitro immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

1 reference

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Reshaping human antibodies for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Molecular classification of cancer: class discovery and class prediction by gene expression monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Antibodies for targeted gene therapy: extracellular gene targeting and intracellular expression

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

A review of interleukin-2 receptor antagonists in solid organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Signaling antibodies in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Making antibody fragments using phage display libraries

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Isolation of high affinity human antibodies directly from large synthetic repertoires.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Exploiting recombination in single bacteria to make large phage antibody libraries

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Tailoring in vitro evolution for protein affinity or stability

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Psoralen photo-crosslinked mRNA-puromycin conjugates: a novel template for the rapid and facile preparation of mRNA-protein fusions

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

PROfusion: genetically tagged proteins for functional proteomics and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

Evolution of a cytokine using DNA family shuffling

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4892%2801%2900070-4

7 January 2021

10.1016/S1471-4892(01)00070-4

Identifiers

DOI

1 reference

2 August 2017

1 reference